news

Blood cancer study yields disappointing results

0
SHARES

Posted: 19 July 2016 | | No comments yet

Gazyvaro did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with diffuse large B-cell lymphoma…

Swiss drugmaker Roche today announced that the Phase III GOYA study of Gazyvaro (obinutuzumab, also known in the US as Gazyva) did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with previously untreated diffuse large B-cell lymphoma compared to Rituxan (rituximab), an alternative, when combined with CHOP chemotherapy.  

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Unfortunately, adverse effects with both Gazyvaro and Rituxan were consistent with those seen in previous clinical trials when each was combined with various chemotherapies. These effects, and all other data, will be presented at an upcoming medical meeting.

“Two previous studies showed Gazyvaro helped people with previously untreated follicular lymphoma or chronic lymphocytic leukaemia live longer without their disease worsening compared to Rituxan. We were hopeful to show a similar result for people with diffuse large B-cell lymphoma and once again improve on the standard of care”, said Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development.

“We will continue to analyse the GOYA data to better understand the results, and to study other investigational treatments in this disease with the goal of further helping these patients”.

Gazyvaro is currently approved in more than 70 countries in combination with chlorambucil for people with previously untreated chronic lymphocytic leukaemia.

Successful clinical trials would not only help fend off cheaper competition for biosimilar copies of both Rituxan and Gazyvaro, which are to be available on the market within the next couple of years, but also help a much wider range of cancer patients with successful treatments.

Diffuse large B-cell lymphoma is the most common form of non-Hodgkin’s lymphoma with an estimated 25,000 new US cases of the aggressive blood cancer, and 10,000 deaths from it seen each year.